Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 8/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23914851 | 0.90 | S1PR2 (0.49) | S1PR2AKR1B1EGLN1PARP1 | |
| SCHEMBL23915343 | 0.90 | S1PR2 (0.58) | S1PR2AKR1B1 | |
| SCHEMBL23908873 | 0.89 | S1PR2 (0.68) | S1PR2AKR1B1MAPT | |
| SCHEMBL23908772 | 0.89 | S1PR2 (0.53) | S1PR2AKR1B1PARP1 | |
| SCHEMBL23914679 | 0.88 | S1PR2 (0.56) | S1PR2AKR1B1 | |
| SCHEMBL23908998 | 0.84 | S1PR2 (0.83) | S1PR2AKR1B1 | |
| SCHEMBL23915330 | 0.80 | S1PR2 (0.56) | S1PR2MAPTTP53 | |
| SCHEMBL23966580 | 0.79 | S1PR2 (0.55) | S1PR2AKR1B1MAPTPTGDR2 | |
| SCHEMBL23908754 | 0.78 | S1PR2 (0.67) | S1PR2AKR1B1PTGDR2 | |
| SCHEMBL23908751 | 0.78 | S1PR2 (0.67) | S1PR2AKR1B1EGLN1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | S1PR2 3/4885AKR1B1 124/4885EGLN1 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.